Company Filing History:
3 out of 850 
2 out of 26 
Years Active: 2018-2024
Title: Innovator Spotlight: Nibedita Chattopadhyay
Introduction: Nibedita Chattopadhyay is an accomplished inventor based in Wellesley, MA, known for her significant contributions to the field of biotechnology. With a remarkable portfolio that includes three patents, Nibedita is an influential figure in the development of targeted therapies for cancers and other disorders.
Latest Patents: One of Nibedita Chattopadhyay's latest inventions is a groundbreaking patent that focuses on CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors. This innovative invention provides binding proteins that include a CD38-binding region for cell-targeting along with a Shiga toxin A Subunit effector polypeptide. The Shiga toxin effector polypeptides are modified to enhance safety through de-immunization and reduced protease sensitivity while retaining essential functions, such as stimulating cellular internalization and directing intracellular routing. These CD38-binding proteins hold promise for selective killing of specific CD38-expressing cell types and are particularly relevant in the diagnosis and treatment of CD38-positive hematopoietic cancers, like multiple myeloma.
Career Highlights: Throughout her career, Nibedita Chattopadhyay has demonstrated exceptional expertise in biotechnology and therapeutic innovation. She has worked with prominent companies, including Millennium Pharmaceuticals Limited and Molecular Templates, Inc., where she contributed to cutting-edge research and product development that has the potential to change the landscape of cancer treatment.
Collaborations: Nibedita has collaborated with esteemed colleagues in her field, including Eric Poma and Erin Willert. These collaborations have enriched her research endeavors and facilitated the advancement of novel therapeutic solutions.
Conclusion: Nibedita Chattopadhyay is a commendable inventor whose work in developing CD38-binding proteins exemplifies the potential of biotechnology in fighting cancer. Her innovative approach to harnessing the power of de-immunized Shiga toxin subunits has opened new avenues for targeted therapies, making her a notable figure in the realms of innovation and invention.